Literature DB >> 14506167

Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization.

Jeffery S Russell1, William Burgan, Kelli A Oswald, Kevin Camphausen, Philip J Tofilon.   

Abstract

PURPOSE: Current strategies for tumor cell radiosensitization focus on a target-based approach. However, the radioresponse of a tumor cell is influenced by a wide variety of signaling molecules existing in a number of different survival pathways. Therefore, in an attempt to increase the probability and/or degree of radiosensitization, we have begun to investigate a multitarget approach using the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG). EXPERIMENTAL
DESIGN: The effect of 17AAG on the levels of three proteins (Raf-1, ErbB2, and Akt) previously implicated in the regulation of radiosensitivity was determined in four human tumor cell lines. Tumor cell survival after exposure to corresponding concentrations of 17AAG combined with clinically relevant doses of X-rays was then evaluated using a clonogenic assay. The radiosensitivity of a nonimmortalized, normal fibroblast cell line was also determined after exposure to 17AAG.
RESULTS: Exposure to nanomolar concentrations of 17AAG reduced the levels of the three radiosensitivity-associated proteins in a cell type manner. Using corresponding concentrations, 17AAG enhanced the radiosensitivity of each of the tumor cell lines with enhancement factors ranging from 1.3 to 1.7. The enhancement appeared to be related to the number of radioresponse-regulatory proteins affected. In contrast to the tumor cell lines, 17AAG had no effect on the radiosensitivity of a normal, nonimmortalized human fibroblast cell line.
CONCLUSIONS: These data suggest that heat shock protein 90 may be an appropriate target for selectively enhancing the radiosensitivity of tumor cells over normal cells. Furthermore, they illustrate the potential of a multitarget approach to radiosensitization.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14506167

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  40 in total

1.  Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer.

Authors:  Junqiang Tian; Hongjuan Zhao; Rosalie Nolley; Stephen W Reese; Sarah R Young; Xuejun Li; Donna M Peehl; Susan J Knox
Journal:  Clin Cancer Res       Date:  2012-04-25       Impact factor: 12.531

2.  Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation.

Authors:  Yifan Wang; Hui Liu; Lixia Diao; Adam Potter; Jianhu Zhang; Yawei Qiao; Jing Wang; David A Proia; Ramesh Tailor; Ritsuko Komaki; Steven H Lin
Journal:  Clin Cancer Res       Date:  2016-06-28       Impact factor: 12.531

3.  Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha.

Authors:  Woo-Young Kim; Seung Hyun Oh; Jong-Kyu Woo; Waun Ki Hong; Ho-Young Lee
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

4.  Inhibition of heat shock induction of heat shock protein 70 and enhancement of heat shock protein 27 phosphorylation by quercetin derivatives.

Authors:  Rongsheng E Wang; Jeffrey L-F Kao; Carolyn A Hilliard; Raj K Pandita; Joseph L Roti Roti; Clayton R Hunt; John-Stephen Taylor
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

5.  Hsp90 Inhibitors NVP-AUY922 and NVP-BEP800 May Exert a Significant Radiosensitization on Tumor Cells along with a Cell Type-Specific Cytotoxicity.

Authors:  Natalia Niewidok; Linda-Jacqueline Wack; Sarah Schiessl; Lavinia Stingl; Astrid Katzer; Bülent Polat; Vladimir L Sukhorukov; Michael Flentje; Cholpon S Djuzenova
Journal:  Transl Oncol       Date:  2012-10-01       Impact factor: 4.243

6.  Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma.

Authors:  Junichi Okamoto; Iwao Mikami; Yuichi Tominaga; Kristopher M Kuchenbecker; Yu-Ching Lin; Dawn T Bravo; Genevieve Clement; Adam Yagui-Beltran; M Roshni Ray; Kiyoshi Koizumi; Biao He; David M Jablons
Journal:  J Thorac Oncol       Date:  2008-10       Impact factor: 15.609

7.  Oxidative stress plays a critical role in inactivating mutant BRAF by geldanamycin derivatives.

Authors:  Yayoi Fukuyo; Masahiro Inoue; Takuma Nakajima; Ryuji Higashikubo; Nobuko T Horikoshi; Clayton Hunt; Anny Usheva; Michael L Freeman; Nobuo Horikoshi
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

8.  Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.

Authors:  L Stingl; T Stühmer; M Chatterjee; M R Jensen; M Flentje; C S Djuzenova
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

9.  Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls.

Authors:  J E Bohonowych; U Gopal; J S Isaacs
Journal:  J Oncol       Date:  2010-06-24       Impact factor: 4.375

Review 10.  Hsp90 inhibitors as promising agents for radiotherapy.

Authors:  Alexander E Kabakov; Vladimir A Kudryavtsev; Vladimir L Gabai
Journal:  J Mol Med (Berl)       Date:  2009-11-28       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.